Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Liabilities from Discontinued Operations: 2016

  • Niagen Bioscience's Liabilities from Discontinued Operations was N/A to $184,766 in Q4 2016 from the same period last year, while for Dec 2016 it was $184,766, marking a year-over-year change of. This contributed to the annual value of $184,766 for FY2016, which is N/A change from last year.
  • Per Niagen Bioscience's latest filing, its Liabilities from Discontinued Operations stood at $184,766 for Q4 2016.
  • Over the past 5 years, Niagen Bioscience's Liabilities from Discontinued Operations peaked at $184,766 during Q4 2016, and registered a low of $184,766 during Q4 2016.
  • For the 1-year period, Niagen Bioscience's Liabilities from Discontinued Operations averaged around $184,766, with its median value being $184,766 (2016).